EGFR-TKIs were demonstrated to be safe and significantly efficacious in EGFR mutated NSCLC patients with BM, leading to a median progression-free survival of 14.5 months, a median OS of 21.9 months 11 and intracranial disease response rates of 75-88% 12-14. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.